12:11 EDT Ocuphire Pharma up 12% to $4.37 after FDA posts approval of Ryzumvi
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUP:
- Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
- Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
- Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
- Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
- Ocuphire Pharma provides anticipated 2023 milestones